Ivax Paclitaxel Will Remain On Market; Taxol Generic Has 40% Share
Executive Summary
Ivax' generic paclitaxel has taken just 40% of the paclitaxel market, in part because Bristol-Myers Squibb has reduced the price of Taxol significantly, Ivax said in a Jan. 15 citizen petition submitted to FDA
You may also be interested in...
Cardinal Generic Drug Distribution Reimbursement Shifting As Prices Drop
Cardinal Health is experimenting with several reimbursement procedures in response to the recent change in generic drug manufacturers' pricing strategy
Cardinal Generic Drug Distribution Reimbursement Shifting As Prices Drop
Cardinal Health is experimenting with several reimbursement procedures in response to the recent change in generic drug manufacturers' pricing strategy
Bristol De-Lists ABI Taxol Patent Under Settlement With Ivax
Bristol-Myers Squibb is de-listing the American BioSciences paclitaxel patent that threatened the continued marketing of generic versions of Taxol